Based on Koot and the CEO here are some facts :
In summary the upcoming catalysts are:
Commercial launch of Iluvien in Germany, UK, etc. in Q2-2013
NDA Resubmission to the FDA by end of Q1-2013
Sales of Iluvien in the EU
Marketing authorization in Italy
PDUFA Q3 2013 in US
Possible Iluvien launch in the US Q4 2013
Sentiment: Strong Buy